Company Filing History:
Years Active: 2018-2025
Title: Niklas Bergh: Innovator in Fibrinolysis Treatment
Introduction
Niklas Bergh is a notable inventor based in Sweden, recognized for his contributions to medical science, particularly in the treatment of conditions associated with fibrin deposition and thrombus formation. His innovative work focuses on developing compounds and methods that enhance the body's natural fibrinolytic processes.
Latest Patents
Niklas Bergh holds several significant patents, including:
1. **Compounds And Compositions For The Treatment Or Prevention Of Pathological Conditions Associated With Excess Fibrin Deposition AND/OR Thrombus Formation** - This patent involves the use of valproic acid, or a pharmaceutically acceptable salt thereof, for treating or preventing conditions related to excess fibrin deposition and thrombus formation. The treatment is designed to administer valproic acid in a specific manner to achieve optimal results.
2. **Compounds And Methods For Improving Impaired Endogenous Fibrinolysis Using Histone Deacetylase Inhibitors** - This patent presents a histone deacetylase (HDAC) inhibitor, or its pharmaceutically acceptable derivatives, aimed at treating conditions associated with excess fibrin deposition. It also focuses on enhancing the degradation of fibrin deposits and normalizing impaired endogenous fibrinolysis due to inflammation.
Career Highlights
Niklas Bergh is currently associated with Cereno Scientific AB, where he applies his expertise in developing innovative therapeutic solutions. His work is pivotal in advancing treatments that address critical health issues related to blood clotting and fibrinolysis.
Collaborations
Niklas collaborates with esteemed colleagues, including Pia Larsson and Sverker Jern, to further enhance the research and development of effective medical treatments.
Conclusion
Niklas Bergh's innovative contributions to the field of medical science, particularly in fibrinolysis treatment, highlight his commitment to improving patient outcomes. His patents reflect a deep understanding of complex medical conditions and a dedication to advancing therapeutic options.